KOTRASEETHA RAM1*,PERAVALIJB2,ANMOL KUMAR1, KRS SAMBASIVA RAO1,KK PULICHERLA
Every year most of the deaths were leaded by cardio and cerebrovascular disorders around the globe. The use of first or second generation thrombolytics may rise several side effects like bleeding in biological system at the time of treatment. New generation thrombolytics plays an important role in the treatment of thromboembolic disorders which leads to the death. An ideal fibrin specific plasminogen activator, staphylokinase converts a precursor, plasminogen toactive enzyme, plasmin to dissolve the blood clot during thrombolytic therapy and italso capable to destroy the normal components of haemostatic system which leads to life threatening consequence and also death. Out of four different thrombolytics which are available in market like alteplase, reteplase, streptokinase and tenecteplase, streptokinase was widely used drug because of its low cost.But, to overcome the hurdles like bleeding and reocculsion efforts have been made to construct the more potent staphylokinasedevoid of risk. In this review, progressive development on staphylokinase has been discussed.